Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left Shunt
NCT06938347 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300
Last updated 2025-12-03
Summary
This is a phase 3, multicenter, open-label, blinded, crossover trial in which each participant will undergo a randomized sequence of ASI-02 and agitated saline standard of care (SoC) via a saline contrast transthoracic echocardiogram (TTE) study.
Conditions
- Right-To-Left Shunt
Interventions
- DRUG
-
Agitated Saline SoC
The recommended initial dose of agitated saline SoC is approximately 10 mL of saline containing approximately 1 mL of air, per institutional policy, rapidly mixed (approximately 10-20 presses) to manufacture microbubbles. No additives are allowed to the saline, including blood, dextrose, or bacteriostatic saline.
- DRUG
-
ASI-02
Each injection shall utilize one (1) ASI-02 product connected to one (1) pre-filled 10 mL 0.9% sodium chloride (saline) syringe. The ASI-02 investigational product will be connected to a standard luer lock connector and administered in its entirety. The intravenous bolus injected dose of ASI-02 is 9 mL of saline and 1 mL of air.
Sponsors & Collaborators
-
Bright Research Partners
collaborator INDUSTRY -
Agitated Solutions, Inc.
lead INDUSTRY
Principal Investigators
-
Akhil Narang, MD · Northwestern Medicine
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- SINGLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-11-05
- Primary Completion
- 2026-06-30
- Completion
- 2026-06-30
- FDA Drug
- Yes
Countries
- United States
- Canada
Study Locations
More Related Trials
-
Ambrisentan in Single Ventricle
NCT02080637 ·Status: COMPLETED ·Phase: PHASE2
-
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
NCT05598333 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction
NCT00748982 ·Status: COMPLETED ·Phase: PHASE2
-
Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm
NCT00007605 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
NCT02842242 ·Status: COMPLETED ·Phase: PHASE2
-
Fed-Fasted, Single and Multiple Ascending Dose Trial of XEN-D0103
NCT02390258 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831
NCT04407091 ·Status: COMPLETED ·Phase: PHASE1
-
Study on the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2004 Injection in Adult Patients With Atrial Fibrillation
NCT06280768 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion
NCT06466278 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy
NCT05233163 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
NCT04986202 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
NCT05305911 ·Status: RECRUITING ·Phase: PHASE2
-
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
NCT04988386 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients
NCT00655538 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
NCT03860935 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy
NCT07241104 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver Function
NCT05419635 ·Status: COMPLETED ·Phase: PHASE1
-
Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
NCT06953726 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter
NCT01839357 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction
NCT04836182 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess Cardiac Conduction of GSK1349572
NCT00996021 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation
NCT03087487 ·Status: COMPLETED
-
Effect of Sodium Glucose Cotransporter 2 Inhibitiors on Left Ventricular Remodeling Among Diabetic and Non Diabetic Patients With Chronic Heart Failure
NCT06137430 ·Status: NOT_YET_RECRUITING
-
Comparison of Squat-to-Stand Maneuver With Amyl Nitrite, Valsalva, and Exercise Stress Echocardiography in Inducing Latent Left Ventricular Outflow Obstruction in Hypertrophic Cardiomyopathy
NCT04905173 ·Status: WITHDRAWN ·Phase: NA
-
Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation
NCT01483183 ·Status: TERMINATED ·Phase: PHASE1